Horizon Discovery has announced a new collaboration and license agreement with Mammoth Biosciences, in order to access the company’s novel CRISPR platform and facilitate a new generation of genetically engineered CHO cells. The collaboration means that the companies will put their heads together to optimise certain CRISPR tools to “rapidly develop proprietary CHO cell lines”, in which selected genes are ‘knocked out’ to improve performance parameters. Source: Pharmatimes 14/1/2020